Wisp and Visby Medical Launch First FDA-Authorized At-Home PCR STI…

Event summary

Wisp partners with Visby Medical to offer FDA-authorized at-home PCR STI test for chlamydia, gonorrhea, and trichomoniasis.
Test delivers lab-quality results in 30 minutes via mobile app, with Wisp providing follow-up telehealth care.
Program initially targets specific patient outreach, with plans to expand access over time.
Wisp serves 1.8+ million patients nationwide as the largest pure-play women’s telehealth provider in the U.S.

The big picture

This partnership aligns with the growing trend of decentralized healthcare, where diagnostic tools and telehealth services converge to improve accessibility. Wisp’s integration of Visby’s rapid PCR testing underscores a strategic shift toward seamless, at-home solutions for sensitive health conditions. The collaboration also reflects broader industry efforts to reduce barriers in sexual health care, particularly for underserved populations.

What we're watching

Market Expansion: How quickly Wisp and Visby can scale the program beyond targeted outreach to broader patient populations.
Regulatory Compliance: Whether the FDA-authorized test maintains compliance as new STI variants emerge or testing protocols evolve.
Competitive Dynamics: The pace at which competitors adopt similar integrated testing and telehealth models for STI care.